Company intelligence / Profile preview

Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~8264
Development stage: Other

Overview

Company has approved products including Recombinant Human Interleukin-2(125Ser) for Rheumatoid Arthritis and Recombinant human interferon alpha-2b for Lymphoma, with additional programs in Phase 2 and Phase 1.

Therapeutic areas: ImmunologyCardiovascularEndocrinologyNeurologyInfectious DiseasesPulmonologyGastroenterologyOncology
Modalities: Small moleculeInterferonsInterleukinsHerbal medicine
Industry: Biotech

Partnerships

GSK (former JV in Shenzhen GSK-Neptunus Biologicals Co. Ltd. for influenza vaccines)

Beyond the preview

Go deeper on Shenzhen Neptunus Bioengineering Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Neptunus Bioengineering Co., Ltd..

Explore the full profile